1. Search Result
Search Result
Results for "

benzenesulfonamide

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

10

Peptides

4

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103001

    Others Cancer
    HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
    HMN-154
  • HY-W777823

    Isotope-Labeled Compounds Others
    N-(a,a-Dimethylbenzyl)benzenesulfonamide- 13C6 is the 13C-labeled N-(2-Phenylpropan-2-yl)benzenesulfonamide (HY-W701611).
    N-(a,a-Dimethylbenzyl)benzenesulfonamide-13C6
  • HY-W710871

    Isotope-Labeled Compounds Others
    N,N-Bis(2-chloroethyl)benzenesulfonamide-d5 is the deuterium labeled N,N-Bis(2-chloroethyl)benzenesulfonamide (HY-W703633).
    N,N-Bis(2-chloroethyl)benzenesulfonamide-d5
  • HY-I0006R

    Reference Standards
    N-[6-Chloro-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-4-(1,1-dimethylethyl)-Benzenesulfonamide (Standard) is the analytical standard of N-[6-Chloro-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-4-(1,1-dimethylethyl)-Benzenesulfonamide. This product is intended for research and analytical applications.
    N-[6-Chloro-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-4-(1,1-dimethylethyl)-Benzenesulfonamide (Standard)
  • HY-W394717

    PGN 1531

    Prostaglandin Receptor PKA Others
    BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhancing the ATPase activity, which are coupled to Gs proteins and thus activate adenylate cyclase generating cAMP and activating PKA. BGC-20-1531 is promising for research of liver disorders .
    BGC-20-1531
  • HY-161814

    Apoptosis Metabolic Disease
    Apoptosis inducer 20 (12) causes G2/M cell cycle arrest and induction of apoptosis via caspase 3/7 activation, which occurred during M arrest. Apoptosis inducer 20 is a novel indolic benzenesulfonamide with anti-proliferative effect against a broad panel of cancer cell lines, which is proming for research of new anti-mitotic agents .
    Apoptosis inducer 20
  • HY-W010995S

    Isotope-Labeled Compounds Others
    4-(5-(2,5-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide-d4 is the deuterium labeled 4-(5-(2,5-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide .
    2,5-Dimethylcelecoxib-d4
  • HY-146010

    Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 13 (compound 7) is a potent carbonic anhydrase (CA) inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker .
    Carbonic anhydrase inhibitor 13
  • HY-159132

    Carbonic Anhydrase Cancer
    CAIX/CAXII-IN-2 (compound 23) is a CAIX/CAXII inhibitor, with Ki values ​​of 8.9 nM and 5.3 nM for CAIX/CAXII, respectively. CAIX/CAXII-IN-2 can be used in cancer research .
    CAIX/CAXII-IN-2
  • HY-147961

    COX Inflammation/Immunology
    COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.
    COX-2-IN-23
  • HY-W191560S

    4-Amino-N-(4-nitrophenyl)benzenesulfonamide-d4

    Isotope-Labeled Compounds Others
    N1-(4-Nitrophenyl)sulfanilamide-d4 is the deuterium labeled N1-(4-Nitrophenyl)sulfanilamide.
    N1-(4-Nitrophenyl)sulfanilamide-d4
  • HY-P4154

    ALM-488

    Fluorescent Dye Neurological Disease Cancer
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-162320

    PPAR Metabolic Disease
    PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .
    PPARγ agonist 12
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P1103A

    CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-148135

    Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and >50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-149269

    COX Carbonic Anhydrase LOX-1 Inflammation/Immunology
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect .
    COX-2-IN-30
  • HY-P10026

    LY-3457263

    Neuropeptide Y Receptor Metabolic Disease
    Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .
    Nisotirostide
  • HY-P4757

    Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11293

    Melanocortin Receptor Cancer
    DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
    DOTA-GGNle-CycMSHhex
  • HY-161522

    Glycosidase Carbonic Anhydrase Endocrinology
    α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective. .
    α-Glucosidase-IN-63
  • HY-P1321

    1229U91; GW1229

    Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A

    1229U91 TFA; GW1229 TFA

    Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-P10819

    Histone Demethylase Apoptosis Cancer
    S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .
    S9-CMC1 TFA
  • HY-144791

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-6
  • HY-144792

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: